HDAC Inhibitors: Roles of DNA damage and repair

Advances in Cancer Research

Volumn 116, Issue , 2012, Pages 87-129

  Robert, Carine ^a   Rassool, Feyruz V ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Chromatin remodeling; DNA damage; DNA repair response; Double strand break; Genomic instability; Histone deacetylase inhibitors; Histone deacteylase; Nonhomologous end joining; Sirtuins

Indexed keywords

ATM PROTEIN; ATR PROTEIN; BRCA1 PROTEIN; BRCA2 PROTEIN; CASPASE 3; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; DACINOSTAT; DNA METHYLTRANSFERASE 1; DNA TOPOISOMERASE INHIBITOR; ENTINOSTAT; FLAP ENDONUCLEASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE INHIBITOR; HISTONE H2AX; KU ANTIGEN; MRE11 PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PANOBINOSTAT; RAD50 PROTEIN; RAD51 PROTEIN; ROMIDEPSIN; SIRTUIN 1; TRANSCRIPTION FACTOR E2F1; UNINDEXED DRUG; VORINOSTAT; XERODERMA PIGMENTOSUM GROUP A PROTEIN;

APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL SURVIVAL; CHROMATIN IMMUNOPRECIPITATION; CHROMOSOME TRANSLOCATION; COMPLEX FORMATION; DNA DAMAGE; DNA END JOINING REPAIR; DNA REPAIR; DNA REPLICATION; DOUBLE STRANDED DNA BREAK; DOWN REGULATION; EXCISION REPAIR; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; HISTONE ACETYLATION; HISTONE MODIFICATION; HISTONE PHOSPHORYLATION; HUMAN; KNOCKOUT MOUSE; NONHUMAN; OSTEOSARCOMA; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PROCESSING; RADIOSENSITIVITY; SIGNAL TRANSDUCTION; SPLEEN CELL;

EID: 84867801148     PISSN: 0065230X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-394387-3.00003-3     Document Type: Chapter

References (185)

1. Adams H., Fritzsche F.R., Dirnhofer S., Kristiansen G., Tzankov A. Class I histone deacetylases 1, 2 and 3 are highly expressed in classical Hodgkin's lymphoma. Expert Opinion on Therapeutic Targets 2010, 14:577-584.
2. Alcain F.J., Villalba J.M. Sirtuin inhibitors. Expert Opinion on Therapeutic Patents 2009, 19:283-294.
3. Arundel C.M., Glicksman A.S., Leith J.T. Enhancement of radiation injury in human colon tumor cells by the maturational agent sodium butyrate (NaB). Radiation Research 1985, 104:443-448.
4. Audebert M., Salles B., Calsou P. Effect of double-strand break DNA sequence on the PARP-1 NHEJ pathway. Biochemical and Biophysical Research Communications 2008, 369:982-988.
5. Bakkenist C.J., Kastan M.B. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 2003, 421:499-506.
6. Balaban R.S., Nemoto S., Finkel T. Mitochondria, oxidants, and aging. Cell 2005, 120:483-495.
7. Basile V., Mantovani R., Imbriano C. DNA damage promotes histone deacetylase 4 nuclear localization and repression of G2/M promoters, via p53 C-terminal lysines. The Journal of Biological Chemistry 2006, 281:2347-2357.
8. Bedard K., Krause K.H. The NOX family of ROS-generating NADPH oxidases: Physiology and pathophysiology. Physiological Reviews 2007, 87:245-313.
9. Beucher A., Birraux J., Tchouandong L., Barton O., Shibata A., Conrad S., et al. ATM and Artemis promote homologous recombination of radiation-induced DNA double-strand breaks in G2. The EMBO Journal 2009, 28:3413-3427.
10. Bhalla S., Balasubramanian S., David K., Sirisawad M., Buggy J., Mauro L., et al. PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells. Clinical Cancer Research 2009, 15:3354-3365.
11. Bhaskara S., Chyla B.J., Amann J.M., Knutson S.K., Cortez D., Sun Z.W., et al. Deletion of histone deacetylase 3 reveals critical roles in S phase progression and DNA damage control. Molecular Cell 2008, 30:61-72.
12. Bhaskara S., Knutson S.K., Jiang G., Chandrasekharan M.B., Wilson A.J., Zheng S., et al. Hdac3 is essential for the maintenance of chromatin structure and genome stability. Cancer Cell 2010, 18:436-447.
13. Bindra R.S., Glazer P.M. Repression of RAD51 gene expression by E2F4/p130 complexes in hypoxia. Oncogene 2007, 26:2048-2057.
14. Bolden J.E., Peart M.J., Johnstone R.W. Anticancer activities of histone deacetylase inhibitors. Nature Reviews. Drug Discovery 2006, 5:769-784.
15. Bradbury C.A., Khanim F.L., Hayden R., Bunce C.M., White D.A., Drayson M.T., et al. Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia 2005, 19:1751-1759.
16. Brown D., Kogan S., Lagasse E., Weissman I., Alcalay M., Pelicci P.G., et al. A PMLRARalpha transgene initiates murine acute promyelocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America 1997, 94:2551-2556.
17. Butler L.M., Zhou X., Xu W.S., Scher H.I., Rifkind R.A., Marks P.A., et al. The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proceedings of the National Academy of Sciences of the United States of America 2002, 99:11700-11705.
18. Caldecott K.W. Mammalian single-strand break repair: Mechanisms and links with chromatin. DNA Repair 2007, 6:443-453.
19. Calsou P., Frit P., Humbert O., Muller C., Chen D.J., Salles B. The DNA-dependent protein kinase catalytic activity regulates DNA end processing by means of Ku entry into DNA. The Journal of Biological Chemistry 1999, 274:7848-7856.
20. Camphausen K., Burgan W., Cerra M., Oswald K.A., Trepel J.B., Lee M.J., et al. Enhanced radiation-induced cell killing and prolongation of gH2AX foci expression by the histone deacetylase inhibitor MS-275. Cancer Research 2004, 64:316-321.
21. Carafa V., Nebbioso A., Altucci L. Sirtuins and disease: The road ahead. Frontiers in Pharmacology 2012, 3:4.
22. Carew J.S., Giles F.J., Nawrocki S.T. Histone deacetylase inhibitors: Mechanisms of cell death and promise in combination cancer therapy. Cancer Letters 2008, 269:7-17.
23. Carrassa L., Broggini M., Vikhanskaya F., Damia G. Characterization of the 5'flanking region of the human Chk1 gene: Identification of E2F1 functional sites. Cell Cycle 2003, 2:604-609.
24. Cea M., Soncini D., Fruscione F., Raffaghello L., Garuti A., Emionite L., et al. Synergistic interactions between HDAC and sirtuin inhibitors in human leukemia cells. PLoS One 2011, 6:e22739.
25. Chang J., Varghese D.S., Gillam M.C., Peyton M., Modi B., Schiltz R.L., et al. Differential response of cancer cells to HDAC inhibitors trichostatin A and depsipeptide. British Journal of Cancer 2012, 106:116-125.
26. Chauhan D., Bandi M., Singh A.V., Ray A., Raje N., Richardson P., et al. Preclinical evaluation of a novel SIRT1 modulator SRT1720 in multiple myeloma cells. British Journal of Haematology 2011, 155:588-598.
27. Chen G., Li A., Zhao M., Gao Y., Zhou T., Xu Y., et al. Proteomic analysis identifies protein targets responsible for depsipeptide sensitivity in tumor cells. Journal of Proteome Research 2008, 7:2733-2742.
28. Chen Z.X., Pervaiz S. Bcl-2 induces pro-oxidant state by engaging mitochondrial respiration in tumor cells. Cell Death and Differentiation 2007, 14:1617-1627.
29. Chen C.S., Wang Y.C., Yang H.C., Huang P.H., Kulp S.K., Yang C.C., et al. Histone deacetylase inhibitors sensitize prostate cancer cells to agents that produce DNA double-strand breaks by targeting Ku70 acetylation. Cancer Research 2007, 67:5318-5327.
30. Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C., et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 2009, 325:834-840.
31. Ciccia A., Elledge S.J. The DNA damage response: Making it safe to play with knives. Molecular Cell 2010, 40:179-204.
32. Clement M.V., Stamenkovic I. Superoxide anion is a natural inhibitor of FAS-mediated cell death. The EMBO Journal 1996, 15:216-225.
33. Cohen H.Y., Lavu S., Bitterman K.J., Hekking B., Imahiyerobo T.A., Miller C., et al. Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis. Molecular Cell 2004, 13:627-638.
34. Cohen H.Y., Miller C., Bitterman K.J., Wall N.R., Hekking B., Kessler B., et al. Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science 2004, 305:390-392.
35. Dai Y., Rahmani M., Dent P., Grant S. Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation. Molecular and Cellular Biology 2005, 25:5429-5444.
36. Dasmahapatra G., Lembersky D., Son M.P., Attkisson E., Dent P., Fisher R.I., et al. Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo. Molecular Cancer Therapeutics 2011, 10:1686-1697.
37. Deriano L., Stracker T.H., Baker A., Petrini J.H., Roth D.B. Roles for NBS1 in alternative nonhomologous end-joining of V(D)J recombination intermediates. Molecular Cell 2009, 34:13-25.
38. Dinkelmann M., Spehalski E., Stoneham T., Buis J., Wu Y., Sekiguchi J.M., et al. Multiple functions of MRN in end-joining pathways during isotype class switching. Nature Structural & Molecular Biology 2009, 16:808-813.
39. Drummond D.C., Marx C., Guo Z., Scott G., Noble C., Wang D., et al. Enhanced pharmacodynamic and antitumor properties of a histone deacetylase inhibitor encapsulated in liposomes or ErbB2-targeted immunoliposomes. Clinical Cancer Research 2005, 11:3392-3401.
40. Eot-Houllier G., Fulcrand G., Magnaghi-Jaulin L., Jaulin C. Histone deacetylase inhibitors and genomic instability. Cancer Letters 2009, 274:169-176.
41. Espada J., Esteller M. Epigenetic control of nuclear architecture. Cellular and Molecular Life Sciences 2007, 64:449-457.
42. Falck J., Coates J., Jackson S.P. Conserved modes of recruitment of ATM, ATR and DNA-PKcs to sites of DNA damage. Nature 2005, 434:605-611.
43. Falzon M., Fewell J.W., Kuff E.L. EBP-80, a transcription factor closely resembling the human autoantigen Ku, recognizes single- to double-strand transitions in DNA. The Journal of Biological Chemistry 1993, 268:10546-10552.
44. Fan W., Luo J. SIRT1 regulates UV-induced DNA repair through deacetylating XPA. Molecular Cell 2010, 39:247-258.
45. Fraga M.F., Ballestar E., Villar-Garea A., Boix-Chornet M., Espada J., Schotta G., et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nature Genetics 2005, 37:391-400.
46. Gaymes T.J., Padua R.A., Pla M., Orr S., Omidvar N., Chomienne C., et al. Histone deacetylase inhibitors (HDI) cause DNA damage in leukemia cells: A mechanism for leukemia-specific HDI-dependent apoptosis?. Molecular Cancer Research 2006, 4:563-573.
47. Gong K., Xie J., Yi H., Li W. CS055 (Chidamide/HBI-8000), a novel histone deacetylase inhibitor, induces G1-arrest, ROS-dependent apoptosis and differentiation in human leukemia cells. The Biochemical Journal 2012, 443(3):735-746.
48. Gopal Y.N., Arora T.S., Van Dyke M.W. Parthenolide specifically depletes histone deacetylase 1 protein and induces cell death through ataxia telangiectasia mutated. Chemistry & Biology 2007, 14:813-823.
49. Gore S.D., Baylin S., Sugar E., Carraway H., Miller C.B., Carducci M., et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Research 2006, 66:6361-6369.
50. Gottlieb T.M., Jackson S.P. The DNA-dependent protein kinase: Requirement for DNA ends and association with Ku antigen. Cell 1993, 72:131-142.
51. Hajji N., Wallenborg K., Vlachos P., Fullgrabe J., Hermanson O., Joseph B. Opposing effects of hMOF and SIRT1 on H4K16 acetylation and the sensitivity to the topoisomerase II inhibitor etoposide. Oncogene 2010, 29:2192-2204.
52. Hansen W.K., Kelley M.R. Review of mammalian DNA repair and translational implications. The Journal of Pharmacology and Experimental Therapeutics 2000, 295:1-9.
53. Hartlerode A.J., Scully R. Mechanisms of double-strand break repair in somatic mammalian cells. The Biochemical Journal 2009, 423:157-168.
54. Hayashi T., Ueno Y., Okamoto T. Oxidoreductive regulation of nuclear factor kappa B. Involvement of a cellular reducing catalyst thioredoxin. The Journal of Biological Chemistry 1993, 268:11380-11388.
55. Hirota K., Matsui M., Iwata S., Nishiyama A., Mori K., Yodoi J. AP-1 transcriptional activity is regulated by a direct association between thioredoxin and Ref-1. Proceedings of the National Academy of Sciences of the United States of America 1997, 94:3633-3638.
56. Hofmann B., Hecht H.J., Flohe L. Peroxiredoxins. Biological Chemistry 2002, 383:347-364.
57. Huang P., Plunkett W. Fludarabine- and gemcitabine-induced apoptosis: Incorporation of analogs into DNA is a critical event. Cancer Chemotherapy and Pharmacology 1995, 36:181-188.
58. Huertas P., Jackson S.P. Human CtIP mediates cell cycle control of DNA end resection and double strand break repair. The Journal of Biological Chemistry 2009, 284:9558-9565.
59. Iliakis G. Backup pathways of NHEJ in cells of higher eukaryotes: Cell cycle dependence. Radiotherapy and Oncology 2009, 92:310-315.
60. Insinga A., Monestiroli S., Ronzoni S., Gelmetti V., Marchesi F., Viale A., et al. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nature Medicine 2005, 11:71-76.
61. Ito A., Kawaguchi Y., Lai C.H., Kovacs J.J., Higashimoto Y., Appella E., et al. MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. The EMBO Journal 2002, 21:6236-6245.
62. Jeong J., Juhn K., Lee H., Kim S.H., Min B.H., Lee K.M., et al. SIRT1 promotes DNA repair activity and deacetylation of Ku70. Experimental & Molecular Medicine 2007, 39:8-13.
63. Jiang X., Sun Y., Chen S., Roy K., Price B.D. The FATC domains of PIKK proteins are functionally equivalent and participate in the Tip60-dependent activation of DNA-PKcs and ATM. The Journal of Biological Chemistry 2006, 281:15741-15746.
64. Jin K.L., Pak J.H., Park J.Y., Choi W.H., Lee J.Y., Kim J.H., et al. Expression profile of histone deacetylases 1, 2 and 3 in ovarian cancer tissues. Journal of Gynecologic Oncology 2008, 19:185-190.
65. Johnstone R.W. Histone-deacetylase inhibitors: Novel drugs for the treatment of cancer. Nature Reviews. Drug Discovery 2002, 1:287-299.
66. Kachhap S.K., Rosmus N., Collis S.J., Kortenhorst M.S., Wissing M.D., Hedayati M., et al. Downregulation of homologous recombination DNA repair genes by HDAC inhibition in prostate cancer is mediated through the E2F1 transcription factor. PLoS One 2010, 5:e11208.
67. Kaidi A., Weinert B.T., Choudhary C., Jackson S.P. Human SIRT6 promotes DNA end resection through CtIP deacetylation. Science 2010, 329:1348-1353.
68. Kalle A.M., Mallika A., Badiger J., Alinakhi, Talukdar P., Sachchidanand Inhibition of SIRT1 by a small molecule induces apoptosis in breast cancer cells. Biochemical and Biophysical Research Communications 2010, 401:13-19.
69. Kao G.D., McKenna W.G., Guenther M.G., Muschel R.J., Lazar M.A., Yen T.J. Histone deacetylase 4 interacts with 53BP1 to mediate the DNA damage response. The Journal of Cell Biology 2003, 160:1017-1027.
70. Karagiannis T.C., Kn H., El-Osta A. The epigenetic modifier, valproic acid, enhances radiation sensitivity. Epigenetics 2006, 1:131-137.
71. Kerr E., Holohan C., McLaughlin K.M., Majkut J., Dolan S., Redmond K., et al. Identification of an acetylation-dependant Ku70/FLIP complex that regulates FLIP expression and HDAC inhibitor-induced apoptosis. Cell Death and Differentiation 2012, 19(8):1317-1327.
72. Khan O., La Thangue N.B. HDAC inhibitors in cancer biology: Emerging mechanisms and clinical applications. Immunology and Cell Biology 2012, 90:85-94.
73. Khanna K.K., Jackson S.P. DNA double-strand breaks: Signaling, repair and the cancer connection. Nature Genetics 2001, 27:247-254.
74. Kim G.D., Choi Y.H., Dimtchev A., Jeong S.J., Dritschilo A., Jung M. Sensing of ionizing radiation-induced DNA damage by ATM through interaction with histone deacetylase. The Journal of Biological Chemistry 1999, 274:31127-31130.
75. Kim J.J., Lee S.B., Park J.K., Yoo Y.D. TNF-alpha-induced ROS production triggering apoptosis is directly linked to Romo1 and Bcl-X(L). Cell Death and Differentiation 2010, 17:1420-1434.
76. Kim H.S., Patel K., Muldoon-Jacobs K., Bisht K.S., Aykin-Burns N., Pennington J.D., et al. SIRT3 is a mitochondria-localized tumor suppressor required for maintenance of mitochondrial integrity and metabolism during stress. Cancer Cell 2010, 17:41-52.
77. Kobayashi Y., Furukawa-Hibi Y., Chen C., Horio Y., Isobe K., Ikeda K., et al. SIRT1 is critical regulator of FOXO-mediated transcription in response to oxidative stress. International Journal of Molecular Medicine 2005, 16:237-243.
78. Kobayashi C.I., Suda T. Regulation of reactive oxygen species in stem cells and cancer stem cells. Journal of Cellular Physiology 2012, 227:421-430.
79. Kotian S., Liyanarachchi S., Zelent A., Parvin J.D. Histone deacetylases 9 and 10 are required for homologous recombination. The Journal of Biological Chemistry 2011, 286:7722-7726.
80. Lawson M., Uciechowska U., Schemies J., Rumpf T., Jung M., Sippl W. Inhibitors to understand molecular mechanisms of NAD(+)-dependent deacetylases (sirtuins). Biochimica et Biophysica Acta 2010, 1799:726-739.
81. Lee J.H., Choy M.L., Ngo L., Foster S.S., Marks P.A. Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:14639-14644.
82. Lee S.F., Pervaiz S. Assessment of oxidative stress-induced DNA damage by immunoflourescent analysis of 8-oxodG. Methods in Cell Biology 2011, 103:99-113.
83. Li K., Casta A., Wang R., Lozada E., Fan W., Kane S., et al. Regulation of WRN protein cellular localization and enzymatic activities by SIRT1-mediated deacetylation. The Journal of Biological Chemistry 2008, 283:7590-7598.
84. Li Z.Y., Yang Y., Ming M., Liu B. Mitochondrial ROS generation for regulation of autophagic pathways in cancer. Biochemical and Biophysical Research Communications 2011, 414:5-8.
85. Lindahl T., Wood R.D. Quality control by DNA repair. Science 1999, 286:1897-1905.
86. Liu N., Lamerdin J.E., Tebbs R.S., Schild D., Tucker J.D., Shen M.R., et al. XRCC2 and XRCC3, new human Rad51-family members, promote chromosome stability and protect against DNA cross-links and other damages. Molecular Cell 1998, 1:783-793.
87. Liu T., Liu P.Y., Marshall G.M. The critical role of the class III histone deacetylase SIRT1 in cancer. Cancer Research 2009, 69:1702-1705.
88. Lobrich M., Jeggo P.A. The two edges of the ATM sword: Co-operation between repair and checkpoint functions. Radiotherapy and Oncology 2005, 76:112-118.
89. Louis M., Rosato R.R., Brault L., Osbild S., Battaglia E., Yang X.H., et al. The histone deacetylase inhibitor sodium butyrate induces breast cancer cell apoptosis through diverse cytotoxic actions including glutathione depletion and oxidative stress. International Journal of Oncology 2004, 25:1701-1711.
90. Lukas J., Lukas C., Bartek J. More than just a focus: The chromatin response to DNA damage and its role in genome integrity maintenance. Nature Cell Biology 2011, 13:1161-1169.
91. Luo J., Su F., Chen D., Shiloh A., Gu W. Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature 2000, 408:377-381.
92. Magne N., Toillon R.A., Bottero V., Didelot C., Houtte P.V., Gerard J.P., et al. NF-kappaB modulation and ionizing radiation: Mechanisms and future directions for cancer treatment. Cancer Letters 2006, 231:158-168.
93. Mao Z., Hine C., Tian X., Van Meter M., Au M., Vaidya A., et al. SIRT6 promotes DNA repair under stress by activating PARP1. Science 2011, 332:1443-1446.
94. Marks P.A. Thioredoxin in cancer-Role of histone deacetylase inhibitors. Seminars in Cancer Biology 2006, 16:436-443.
95. Marks P.A., Richon V.M., Rifkind R.A. Histone deacetylase inhibitors: Inducers of differentiation or apoptosis of transformed cells. Journal of the National Cancer Institute 2000, 92:1210-1216.
96. Marquard L., Poulsen C.B., Gjerdrum L.M., de Nully Brown P., Christensen I.J., Jensen P.B., et al. Histone deacetylase 1, 2, 6 and acetylated histone H4 in B- and T-cell lymphomas. Histopathology 2009, 54:688-698.
97. Maynard S., Schurman S.H., Harboe C., de Souza-Pinto N.C., Bohr V.A. Base excision repair of oxidative DNA damage and association with cancer and aging. Carcinogenesis 2009, 30:2-10.
98. McCord R.A., Michishita E., Hong T., Berber E., Boxer L.D., Kusumoto R., et al. SIRT6 stabilizes DNA-dependent protein kinase at chromatin for DNA double-strand break repair. Aging (Albany, NY) 2009, 1:109-121.
99. McGuinness D., McGuinness D.H., McCaul J.A., Shiels P.G. Sirtuins, bioageing, and cancer. Journal of Aging Research 2011, 2011:235754.
100. Memisoglu A., Samson L. Base excision repair in yeast and mammals. Mutation Research 2000, 451:39-51.
101. Mercurio C., Minucci S., Pelicci P.G. Histone deacetylases and epigenetic therapies of hematological malignancies. Pharmacological Research 2010, 62:18-34.
102. Michiels C., Raes M., Toussaint O., Remacle J. Importance of Se-glutathione peroxidase, catalase, and Cu/Zn-SOD for cell survival against oxidative stress. Free Radical Biology & Medicine 1994, 17:235-248.
103. Miller C.P., Singh M.M., Rivera-Del Valle N., Manton C.A., Chandra J. Therapeutic strategies to enhance the anticancer efficacy of histone deacetylase inhibitors. Journal of Biomedicine and Biotechnology 2011, 2011:514261.
104. Miller K.M., Tjeertes J.V., Coates J., Legube G., Polo S.E., Britton S., et al. Human HDAC1 and HDAC2 function in the DNA-damage response to promote DNA nonhomologous end-joining. Nature Structural & Molecular Biology 2010, 17:1144-1151.
105. Mimitou E.P., Symington L.S. Nucleases and helicases take center stage in homologous recombination. Trends in Biochemical Sciences 2009, 34:264-272.
106. Mimori T., Hardin J.A. Mechanism of interaction between Ku protein and DNA. The Journal of Biological Chemistry 1986, 261:10375-10379.
107. Ming M., Shea C.R., Guo X., Li X., Soltani K., Han W., et al. Regulation of global genome nucleotide excision repair by SIRT1 through xeroderma pigmentosum C. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:22623-22628.
108. Minucci S., Pelicci P.G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nature Reviews. Cancer 2006, 6:38-51.
109. Misteli T., Soutoglou E. The emerging role of nuclear architecture in DNA repair and genome maintenance. Nature Reviews. Molecular Cell Biology 2009, 10:243-254.
110. Miyamoto S. Nuclear initiated NF-kappaB signaling: NEMO and ATM take center stage. Cell Research 2011, 21:116-130.
111. Montero A.J., Jassem J. Cellular redox pathways as a therapeutic target in the treatment of cancer. Drugs 2011, 71:1385-1396.
112. Mostoslavsky R., Chua K.F., Lombard D.B., Pang W.W., Fischer M.R., Gellon L., et al. Genomic instability and aging-like phenotype in the absence of mammalian SIRT6. Cell 2006, 124:315-329.
113. Moufarij M.A., Sampath D., Keating M.J., Plunkett W. Fludarabine increases oxaliplatin cytotoxicity in normal and chronic lymphocytic leukemia lymphocytes by suppressing interstrand DNA crosslink removal. Blood 2006, 108:4187-4193.
114. Munshi A., Kurland J.F., Nishikawa T., Tanaka T., Hobbs M.L., Tucker S.L., et al. Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity. Clinical Cancer Research 2005, 11:4912-4922.
115. Munshi A., Tanaka T., Hobbs M.L., Tucker S.L., Richon V.M., Meyn R.E. Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of g-H2AX foci. Molecular Cancer Therapeutics 2006, 5:1967-1974.
116. Murr R., Loizou J.I., Yang Y.G., Cuenin C., Li H., Wang Z.Q., et al. Histone acetylation by Trrap-Tip60 modulates loading of repair proteins and repair of DNA double-strand breaks. Nature Cell Biology 2006, 8:91-99.
117. Nakagawa M., Oda Y., Eguchi T., Aishima S., Yao T., Hosoi F., et al. Expression profile of class I histone deacetylases in human cancer tissues. Oncology Reports 2007, 18:769-774.
118. Nakamura H., Matsuda M., Furuke K., Kitaoka Y., Iwata S., Toda K., et al. Adult T cell leukemia-derived factor/human thioredoxin protects endothelial F-2 cell injury caused by activated neutrophils or hydrogen peroxide. Immunology Letters 1994, 42:75-80.
119. Nalabothula N., Carrier F. Cancer cells' epigenetic composition and predisposition to histone deacetylase inhibitor sensitization. Epigenomics 2011, 3:145-155.
120. Namdar M., Perez G., Ngo L., Marks P.A. Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:20003-20008.
121. Nebbioso A., Clarke N., Voltz E., Germain E., Ambrosino C., Bontempo P., et al. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nature Medicine 2005, 11:77-84.
122. Nebbioso A., Pereira R., Khanwalkar H., Matarese F., Garcia-Rodriguez J., Miceli M., et al. Death receptor pathway activation and increase of ROS production by the triple epigenetic inhibitor UVI5008. Molecular Cancer Therapeutics 2011, 10:2394-2404.
123. Nguyen T., Dai Y., Attkisson E., Kramer L., Jordan N., Nguyen N., et al. HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo. Clinical Cancer Research 2011, 17:3219-3232.
124. Nussenzweig A., Nussenzweig M.C. A backup DNA repair pathway moves to the forefront. Cell 2007, 131:223-225.
125. O'Driscoll M., Jeggo P.A. The role of double-strand break repair-Insights from human genetics. Nature Reviews. Genetics 2006, 7:45-54.
126. O'Hagan H.M., Mohammad H.P., Baylin S.B. Double strand breaks can initiate gene silencing and SIRT1-dependent onset of DNA methylation in an exogenous promoter CpG island. PLoS Genetics 2008, 4:e1000155.
127. Ogiwara H., Ui A., Otsuka A., Satoh H., Yokomi I., Nakajima S., et al. Histone acetylation by CBP and p300 at double-strand break sites facilitates SWI/SNF chromatin remodeling and the recruitment of non-homologous end joining factors. Oncogene 2011, 30:2135-2146.
128. Park J.H., Park E.J., Lee H.S., Kim S.J., Hur S.K., Imbalzano A.N., et al. Mammalian SWI/SNF complexes facilitate DNA double-strand break repair by promoting gamma-H2AX induction. The EMBO Journal 2006, 25:3986-3997.
129. Peng L., Yuan Z., Ling H., Fukasawa K., Robertson K., Olashaw N., et al. SIRT1 deacetylates the DNA methyltransferase 1 (DNMT1) protein and alters its activities. Molecular and Cellular Biology 2011, 31:4720-4734.
130. Pervaiz S., Taneja R., Ghaffari S. Oxidative stress regulation of stem and progenitor cells. Antioxidants & Redox Signaling 2009, 11:2777-2789.
131. Peserico A., Simone C. Physical and functional HAT/HDAC interplay regulates protein acetylation balance. Journal of Biomedicine and Biotechnology 2011, 2011:371832.
132. Petalcorin M.I., Sandall J., Wigley D.B., Boulton S.J. CeBRC-2 stimulates D-loop formation by RAD-51 and promotes DNA single-strand annealing. Journal of Molecular Biology 2006, 361:231-242.
133. Petruccelli L.A., Dupere-Richer D., Pettersson F., Retrouvey H., Skoulikas S., Miller W.H. Vorinostat induces reactive oxygen species and DNA damage in acute myeloid leukemia cells. PLoS One 2011, 6:e20987.
134. Polo S.E., Kaidi A., Baskcomb L., Galanty Y., Jackson S.P. Regulation of DNA-damage responses and cell-cycle progression by the chromatin remodelling factor CHD4. The EMBO Journal 2010, 29:3130-3139.
135. Rahman I., Marwick J., Kirkham P. Redox modulation of chromatin remodeling: Impact on histone acetylation and deacetylation, NF-kappaB and pro-inflammatory gene expression. Biochemical Pharmacology 2004, 68:1255-1267.
136. Rahmani M., Reese E., Dai Y., Bauer C., Payne S.G., Dent P., et al. Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species. Cancer Research 2005, 65:2422-2432.
137. Rajendran R., Garva R., Krstic-Demonacos M., Demonacos C. Sirtuins: Molecular traffic lights in the crossroad of oxidative stress, chromatin remodeling, and transcription. Journal of Biomedicine and Biotechnology 2011, 2011:368276.
138. Rass E., Grabarz A., Plo I., Gautier J., Bertrand P., Lopez B.S. Role of Mre11 in chromosomal nonhomologous end joining in mammalian cells. Nature Structural & Molecular Biology 2009, 16:819-824.
139. Riballo E., Kuhne M., Rief N., Doherty A., Smith G.C., Recio M.J., et al. A pathway of double-strand break rejoining dependent upon ATM, Artemis, and proteins locating to gamma-H2AX foci. Molecular Cell 2004, 16:715-724.
140. Rogakou E.P., Pilch D.R., Orr A.H., Ivanova V.S., Bonner W.M. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. The Journal of Biological Chemistry 1998, 273:5858-5868.
141. Rosato R.R., Almenara J.A., Grant S. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Research 2003, 63:3637-3645.
142. Rosato R.R., Almenara J.A., Maggio S.C., Coe S., Atadja P., Dent P., et al. Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions. Molecular Cancer Therapeutics 2008, 7:3285-3297.
143. Rosato R.R., Kolla S.S., Hock S.K., Almenara J.A., Patel A., Amin S., et al. Histone deacetylase inhibitors activate NF-kappaB in human leukemia cells through an ATM/NEMO-related pathway. The Journal of Biological Chemistry 2010, 285:10064-10077.
144. Rosato R.R., Maggio S.C., Almenara J.A., Payne S.G., Atadja P., Spiegel S., et al. The histone deacetylase inhibitor LAQ824 induces human leukemia cell death through a process involving XIAP down-regulation, oxidative injury, and the acid sphingomyelinase-dependent generation of ceramide. Molecular Pharmacology 2006, 69:216-225.
145. Rossetto D., Truman A.W., Kron S.J., Cote J. Epigenetic modifications in double-strand break DNA damage signaling and repair. Clinical Cancer Research 2010, 16:4543-4552.
146. Roth D.B., Porter T.N., Wilson J.H. Mechanisms of nonhomologous recombination in mammalian cells. Molecular and Cellular Biology 1985, 5:2599-2607.
147. Roth D.B., Wilson J.H. Nonhomologous recombination in mammalian cells: Role for short sequence homologies in the joining reaction. Molecular and Cellular Biology 1986, 6:4295-4304.
148. Ruefli A.A., Ausserlechner M.J., Bernhard D., Sutton V.R., Tainton K.M., Kofler R., et al. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proceedings of the National Academy of Sciences of the United States of America 2001, 98:10833-10838.
149. Saitoh M., Nishitoh H., Fujii M., Takeda K., Tobiume K., Sawada Y., et al. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. The EMBO Journal 1998, 17:2596-2606.
150. Sallmyr A., Tomkinson A.E., Rassool F.V. Up-regulation of WRN and DNA ligase IIIalpha in chronic myeloid leukemia: Consequences for the repair of DNA double-strand breaks. Blood 2008, 112:1413-1423.
151. Sancar A., Lindsey-Boltz L.A., Unsal-Kacmaz K., Linn S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annual Review of Biochemistry 2004, 73:39-85.
152. Sanda T., Okamoto T., Uchida Y., Nakagawa H., Iida S., Kayukawa S., et al. Proteome analyses of the growth inhibitory effects of NCH-51, a novel histone deacetylase inhibitor, on lymphoid malignant cells. Leukemia 2007, 21:2344-2353.
153. Sartori A.A., Lukas C., Coates J., Mistrik M., Fu S., Bartek J., et al. Human CtIP promotes DNA end resection. Nature 2007, 450:509-514.
154. Sattler M., Winkler T., Verma S., Byrne C.H., Shrikhande G., Salgia R., et al. Hematopoietic growth factors signal through the formation of reactive oxygen species. Blood 1999, 93:2928-2935.
155. Scharer O.D., Jiricny J. Recent progress in the biology, chemistry and structural biology of DNA glycosylases. BioEssays 2001, 23:270-281.
156. Scher M.B., Vaquero A., Reinberg D. SirT3 is a nuclear NAD+-dependent histone deacetylase that translocates to the mitochondria upon cellular stress. Genes & Development 2007, 21:920-928.
157. Selvi R.B., Kundu T.K. Reversible acetylation of chromatin: Implication in regulation of gene expression, disease and therapeutics. Biotechnology Journal 2009, 4:375-390.
158. Sharma G.G., So S., Gupta A., Kumar R., Cayrou C., Avvakumov N., et al. MOF and histone H4 acetylation at lysine 16 are critical for DNA damage response and double-strand break repair. Molecular and Cellular Biology 2010, 30:3582-3595.
159. Singleton B.K., Torres-Arzayus M.I., Rottinghaus S.T., Taccioli G.E., Jeggo P.A. The C terminus of Ku80 activates the DNA-dependent protein kinase catalytic subunit. Molecular and Cellular Biology 1999, 19:3267-3277.
160. Sonoda E., Zhao G.Y., Kohzaki M., Dhar P.K., Kikuchi K., Redon C., et al. Collaborative roles of gammaH2AX and the Rad51 paralog Xrcc3 in homologous recombinational repair. DNA Repair 2007, 6:280-292.
161. Sun Y., Jiang X., Chen S., Fernandes N., Price B.D. A role for the Tip60 histone acetyltransferase in the acetylation and activation of ATM. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:13182-13187.
162. Sun Y., Jiang X., Price B.D. Tip60: Connecting chromatin to DNA damage signaling. Cell Cycle 2010, 9:930-936.
163. Sun Y., Jiang X., Xu Y., Ayrapetov M.K., Moreau L.A., Whetstine J.R., et al. Histone H3 methylation links DNA damage detection to activation of the tumour suppressor Tip60. Nature Cell Biology 2009, 11:1376-1382.
164. Sun Y., Xu Y., Roy K., Price B.D. DNA damage-induced acetylation of lysine 3016 of ATM activates ATM kinase activity. Molecular and Cellular Biology 2007, 27:8502-8509.
165. Tao R., Coleman M.C., Pennington J.D., Ozden O., Park S.H., Jiang H., et al. Sirt3-mediated deacetylation of evolutionarily conserved lysine 122 regulates MnSOD activity in response to stress. Molecular Cell 2010, 40:893-904.
166. Tsai H.C., Li H., Van Neste L., Cai Y., Robert C., Rassool F.V., et al. Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell 2012, 21:430-446.
167. Uhl M., Csernok A., Aydin S., Kreienberg R., Wiesmuller L., Gatz S.A. Role of SIRT1 in homologous recombination. DNA Repair 2010, 9:383-393.
168. Ungerstedt J.S., Sowa Y., Xu W.S., Shao Y., Dokmanovic M., Perez G., et al. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:673-678.
169. van der Horst A., Tertoolen L.G., de Vries-Smits L.M., Frye R.A., Medema R.H., Burgering B.M. FOXO4 is acetylated upon peroxide stress and deacetylated by the longevity protein hSir2(SIRT1). The Journal of Biological Chemistry 2004, 279:28873-28879.
170. Wagner J.M., Hackanson B., Lubbert M., Jung M. Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. Clinical Epigenetics 2010, 1:117-136.
171. Walker J.R., Corpina R.A., Goldberg J. Structure of the Ku heterodimer bound to DNA and its implications for double-strand break repair. Nature 2001, 412:607-614.
172. Wang J., Chen J. SIRT1 regulates autoacetylation and histone acetyltransferase activity of TIP60. The Journal of Biological Chemistry 2010, 285:11458-11464.
173. Wang H., Rosidi B., Perrault R., Wang M., Zhang L., Windhofer F., et al. DNA ligase III as a candidate component of backup pathways of nonhomologous end joining. Cancer Research 2005, 65:4020-4030.
174. Wang R.H., Sengupta K., Li C., Kim H.S., Cao L., Xiao C., et al. Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell 2008, 14:312-323.
175. Wang M., Wu W., Rosidi B., Zhang L., Wang H., Iliakis G. PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways. Nucleic Acids Research 2006, 34:6170-6182.
176. Weichert W., Roske A., Gekeler V., Beckers T., Stephan C., Jung K., et al. Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. British Journal of Cancer 2008, 98:604-610.
177. Wyatt M.D., Pittman D.L. Methylating agents and DNA repair responses: Methylated bases and sources of strand breaks. Chemical Research in Toxicology 2006, 19:1580-1594.
178. Xie A., Kwok A., Scully R. Role of mammalian Mre11 in classical and alternative nonhomologous end joining. Nature Structural & Molecular Biology 2009, 16:814-818.
179. Xu W., Ngo L., Perez G., Dokmanovic M., Marks P.A. Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:15540-15545.
180. Xu W.S., Parmigiani R.B., Marks P.A. Histone deacetylase inhibitors: Molecular mechanisms of action. Oncogene 2007, 26:5541-5552.
181. Yamamori T., DeRicco J., Naqvi A., Hoffman T.A., Mattagajasingh I., Kasuno K., et al. SIRT1 deacetylates APE1 and regulates cellular base excision repair. Nucleic Acids Research 2010, 38:832-845.
182. Yang X.J., Seto E. Lysine acetylation: Codified crosstalk with other posttranslational modifications. Molecular Cell 2008, 31:449-461.
183. Yuan H., Wang Z., Li L., Zhang H., Modi H., Horne D., et al. Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis. Blood 2012, 119:1904-1914.
184. Yuan Z., Zhang X., Sengupta N., Lane W.S., Seto E. SIRT1 regulates the function of the Nijmegen breakage syndrome protein. Molecular Cell 2007, 27:149-162.
185. Zhang Z., Yamashita H., Toyama T., Sugiura H., Ando Y., Mita K., et al. Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast. Breast Cancer Research and Treatment 2005, 94:11-16.